Disclosure The following people have no relevant financial, professional or personal relationships to disclose:
|
|
- Clifton Murphy
- 5 years ago
- Views:
Transcription
1 Serodiscordant Couples Deborah Cohan, MD, MPH University of California San Francisco Department of Obstetrics, Gynecology, and Reproductive Sciences Bay Area Perinatal AIDS Center National Perinatal HIV Hotline and Clinicians Network Disclosure The following people have no relevant financial, professional or personal relationships to disclose: Faculty: Deborah Cohan, MD, MPH CNE Program Planner(s): Marsha Marecki, EdD, WHNP-BC Melanie Steilen, RN, BSN, ACRN Iris Stendig-Raskin, MSN, CRNP, WHNP-BC CNE Program Reviewer(s): Iris Stendig-Raskin, MSN, CRNP, WHNP-BC There are no commercial supporters of this activity. Accreditation status does not imply endorsement by NJSNA, CAI, or ANCC of any commercial products or services. Let s be in touch! Natl Perinatal HIV Hotline & Clinicians Network hour/day coverage Reproductive Infectious Disease pager (24/7) ReproID_HIV listserv: sweber@nccc.ucsf.edu
2 Overview Epidemiology of serodiscordance HIV prevention: Pre-Exposure Prophylaxis Reproductive rights and desires Contraception: condoms, IUDs Conception HIV+ female/hiv- male (H+F/H-M) HIV- female/hiv+ male (H-F/H+M) Will not discuss same-sex serodiscordance Epidemiology of HIV Heterosexual Serodiscordance HIV Cost and Services Utilization Study (1996) Probability sample, n=1421 (34,833, 53,177 ) Currently married or with heterosexual partner HIV + WOMEN HIV+ MEN 54% 52% Chen et al. Family Planning Perspectives, 2001 Heterosexual HIV Transmission Partners in Prevention Study (ACV vs plac.) 3297 couples with 86 linked transmissions Unadjusted risk per-unprotected act Male-to-female Female-to-male Each log viral load: 2.9-fold risk per-act Condom use: 78% risk per-act Hughes et al, JID 2012
3 PRE-EXPOSURE PROPHYLAXIS ( PREP ) Pre-Exposure Prophylaxis ARVs for HIV-uninfected prior to exposure Single or dual ARV Daily or intermittent Oral or topical iprex (n=2499 men/mtf sex with men) 44% (p < 0.005) 92% (p < 0.001) if detectable Rx Grant NEJM 2010 DOES PREP WORK FOR HETEROSEXUAL SERODISCORDANT WOMEN AND MEN?
4 Phase III RCT CAPRISA 004 Vaginal TDF 1% gel (2 pericoital doses/24hrs) 889 women, South Africa Efficacy 39% HIV 54% if >80% adherence 51% HSV Karim Science July 2010 VOICE Study (MTN 003) 5,029 women, 15 sites Phase IIb RCT (proof of concept; safety and efficacy) TDF gel vs oral TDF vs oral TDF/FTC vs plac gel/pills DSMB Oral TDF vs. placebo=futile comparison (9/16/2011) TDF gel vs. placebo=futile comparison (11/25/2011) Continuation of TDF/FTC vs. placebo Follow-up planned: open-label CHOICE study if protective effect found FEM-PrEP: Preliminary Results Phase III RCT: daily TDF/FTC vs. placebo Women, yo Study closure reported Feb 18, women screened 2056 enrolled HIV incidence: 4.7/100 P-Y (68 cases): HR 0.94 ( ) Adherence: 95% self report; 86% pill count Level 10ng/ml at 2 visits: 26% non-converters; 15% converters ~75% "not at high risk of HIV" Pregnancy: 11.2% TDF/FTC vs. 7.5% placebo Highest if OCPs Van Damme L et al. CROI; Seattle, 2012; Abst. 32LB.; Taylor D et al. International Microbicides Conference, Sydney, 2012.
5 Partners PrEP Study Phase 3 RCT: oral TDF vs. TDF/FTC vs. placebo 4758 HIV men/women in serodiscordant couples 9 trial sites in Africa July 10, 2011 DSMB meeting placebo arm closed HIV incidence: TDF 67% ; TDF/FTC 75% Partners PrEP Study >80% adherence, 95% efficacy Baeten/Donnell, CROI, 2012 TDF-2/Bostwana Phase III RCT: oral TDF/FTC vs. placebo yo men and women; n=1200 final analysis Overall HIV incidence: 62.6% with TDF/FTC 9/601 TDF/FTC vs. 24/599 placebo Women: 7 vs. 14 cases = 49.4% (p=0.11) Men: 2 vs. 10 cases = 80.1% (p=0.026) If drug supply confirmed, 77.9% with TDF/FTC Women: 3 vs. 13 cases = 75.5% (p=0.021) Men: 1 vs. 6 cases = 82.4% (p=0.065) Thigpen et al IAS, Rome, 2011
6 Summary of PrEP among Women: Adherence is everything! 1% TDF gel VOICE: no difference vs. placebo (why?) CAPRISA: 54% if >80% adherent Oral TDF VOICE: no difference vs. placebo (why?) Partners PrEP: 67% vs. placebo Oral TDF/FTC FEM-PrEP: no difference vs. placebo; adherence! Partners PrEP: 95% if >80% adherent TDF-2: 76% if drug supply confirmed Oral PrEP likely works if taken, but Who is a good candidate? Only SDC? Who will prescribe, monitor? HIV clinics not equipped to manage HIV-neg pts Women s health clinics not equipped to manage PrEP Who will pay (public, private sector)? How to optimize adherence in clinical setting? Alternative PrEP formulations? RAL vaginal gel, Injectable rilpivirine, Dapivarine ring WHAT ABOUT REPRODUCTIVE HEALTH AND SERODISCORDANT COUPLES?
7 A SERODISCORDANT COUPLE DOESN T WANT TO GET PREGNANT! Unintended pregnancy US general population 49% pregnancies unintended US, WIHS 232 adults 77% pregnancies while using contraception (vs. 60% HIV-) US 1090 adolescents 83.3% unplanned 49-52% HIV status known Italy 334 on ARV 57.6% unplanned Finer/Henshaw Perspec Sex Repro Health 2006; Massad AIDS 2004; Koenig AJOG 2007; Floridia Antivir Ther 2006 Contraception Failure (1st Year) Withdrawal/Rhythm Diaphragm Condom Pill 3% 6% 9% 14% 19% 20% Copper IUD 0.5% 0.8% Tubal Ligation 0.5% Injectable Progestin 0.2% Implants 0.1% Vasectomy 0.02% Typical Lowest Expected 0% 5% 10% 15% 20% Hatcher: Contraceptive Technology 16th Edition 1994.
8 IUDs are safe for HIV+ women No evidence of infectious complications 156 HIV+, 493 HIV- (Kenya; Copper IUD) Overall 24 mos: HR 1.0 ( ) No evidence of genital tract shedding of HIV Copper IUD n=98 (Kenya): 4 mos s/p insertion: OR 0.6 ( ) LNG-IUS (Mirena) n=12: no difference pre vs. post-insertion WHO Medical Eligibility Criteria category 2 Benefits generally outweigh theoretical or proven risk Morrison BJOG 2001; Sinei Lancet 1998; Richardson AIDS 1999; Heikinheimo Human Repro 2006 WE WANT TO GET PREGNANT! Fertility desires among HIV+ US reproductive-aged women 35% Cross-sectional, n=118 Rochester 20% yes, 15% unsure 12% tubal regret (4% tubal regret in US) Cross-sectional, n=182 Cross-sectional, n=181 HCSUS probability sample, n=1421 British Columbia 25.8% Baltimore 59% US, HCSUS 29% women (51% if in SDC) 28% men (46% if in SDC) ¹Chen Fam Plann Persp 2001, ²Stanwood Contraception 2007, ³Ogilvie AIDS 2007, 4 Oladapo J Natl Med Assoc 2005, Finocchario Kessler AIDS Behav 2010
9 Being infected with HIV dampens but does not come close to eliminating individuals desires and intentions to have children. Chen et al. Family Planning Perspectives, 2001 Conception for HIV+ female/hiv- male Timed coitus PrEP to HIV- man Vaginal insemination Timed, Unprotected Intercourse Timing unprotected sex with ovulation Barriero et al 62 HIV serodiscordant couples, 22 H+F/H-M Female receiving suppressive ART No cases of sexual HIV transmission P. Barriero, A. Duerr, K. Beckerman et al. Reproductive options for HIV-serodiscordant couples, AIDS Reviews, vol. 8, pp , 2006.
10 Vaginal Insemination #1: Ovulation detection #2: Semen collected into condom or clean cup #3: Semen aspirated into needleless syringe #4: Vaginal insemination by her or partner Vaginal Insemination by Female Vaginal Insemination by Male Partner
11 CONCEPTION FOR HIV- FEMALE/ HIV+ MALE Options for safe conception? COST=yes EFFECTIVENESS=?? Timed coitus PrEP/PEP for HIV- ARV for HIV+ Sperm washing + IUI Sperm washing + IVF-ICSI Adoption, sperm donation, not having children Timed Coitus Sex without a condom during ovulation Ovulation prediction: BBT, spinnbarkeit, urine kit French cohort 104 pregnancies among 92 HIV- ( ) ARV use in 21 men Monthly HIV testing during pregnancy 1/3 inconsistent or no condom use 4 conversions (all inconsistent condom use) 2 at 7 months gestation 2 postpartum Data pre-haart Mandelbrot Lancet 1997
12 Options for safe conception? COST=yes EFFECTIVENESS=?? Timed coitus PrEP/PEP for HIV- ARV for HIV+ Sperm washing + IUI Sperm washing + IVF-ICSI Adoption, sperm donation, not having children Semen and HIV Components HIV present? Spermatozoa NO Seminal fluid possible Non-sperm cells (wbc) possible Spermatozoa No CD4, CCR5 and CXCR4 receptors Electron microscopy suggesting HIV viral particles in sperm not replicated Baccetti J Cell Biol Assisted Reproduction: Sperm Washing Gradient centrifugation separates out 3 components Sperm washed x 2 Use in setting of HIV pioneered by Deborah Anderson & Augusto Enrico Semprini
13 What is done with washed sperm? Intrauterine Insemination (IUI) Europe/Israel (CREAThE), South America MA, CO, OR, MO, TX, CA In-vitro fertilization (IVF) Intracytoplasmic sperm injection (ICSI) Results of Assisted Reproduction Single case of seroconversion with sperm washing/iui (1990) No density gradient, no semen VL prior to IUI CDC recommends against insemination with semen from HIV-infected men IUI IVF/ ICSI 3900 cycles 1184 couples 11 studies 738 cycles 579 couples 10 studies Pregnancy/ cycle Cumulative pregnancy Spont. Abortion 18% 50% 15.6% 38.1% 52.9% 20.6% No seroconversions at birth, 3 months, 6 months Vitorino Fert Ster 2011; Sauer Hum Reprod. 2007, Savasi Hum Repro 2007, Politch, Repro Immun, 2002 Assisted Reproductive Services
14 Options for safe conception? COST=yes EFFECTIVENESS=?? Timed coitus PrEP/PEP for HIV- ARV for HIV+ Sperm washing + IUI Sperm washing + IVF-ICSI Adoption, sperm donation, not having children PrEP for Conception: PrEP-ception Observational cohort HIV+ men on ARVs; HIV-RNA <50 copies/ml x >3 mos HIV-RNA in semen undetectable at baseline Ovulation predictor kit TDF 36 hrs and 12 hours before sex Outcomes: March 2004-March H-F/H+M couples, 46 opted for PrEP Pregnancy rate per # attempts 1 attempt 26% 5 attempts 66% 12 attempts 75% No seroconversions or adverse events Vernazza et al AIDS 2011 Options for safe conception? COST=yes EFFECTIVENESS=?? Timed coitus PrEP/PEP for HIV- ARV for HIV+ Sperm washing + IUI Sperm washing + IVF-ICSI Adoption, sperm donation, not having children
15 Antiretrovirals=Enough? Transmission Barriero, 2006 Cohort 62 SDC 0 Attia, 2009 Meta-analysis 11 cohorts 5021 SDC Donnell Partners in Prevention, 2010 RCT ACV vs. placebo 3381 SDC 349 initiated ARVs 0 (HAART and VL <400) 1 case/273 P-Y w/in 18 days of ARV initiation (vs. 102/4558 P-Y) 92% HPTN 052, 2011 RCT immediate vs. delayed ARV (CD ) 1763 SDC Delayed: 3.1% Immediate: 0.1% 96% Barriero JAIDS 2006; Attia AIDS 2009, Donnell Lancet 2010; Cohen NEJM 2011 The future is now. Numerous methods to decrease HIV transmission while trying to conceive. Logistical, financial barriers Mindset that CD4 count should guide ART initiation Swiss Federal Commission for HIV/AIDS HIV-positive people with no other STIs and on effective antiretroviral therapy do not transmit HIV sexually Antiretroviral therapy is taken consistently. Viral load has been undetectable for at least six months. January 2008
16 Take it home Call the perinatal hotline available 24/7 Serodiscordance common in heterosexual HIV-affected couples PrEP for WSM and MSW likely effective if good adherence (adherence probably driven by perception of risk) Safer conception options = harm reduction Couples will try to conceive with or without your help so, you may as well help Thank you! Do we have to fill our patients lives with years or those years with life? Augusto Enrico Semprini
Reproductive Health for HIV+ Women.. And Men!
Reproductive Health for HIV+ Women.. And Men! I have no financial conflicts of interest. Deborah Cohan, MD, MPH Bay Area Perinatal AIDS Center National Perinatal HIV Hotline and Clinicians Network Objectives
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationDisclosure. Objective
Clinical Consultation: The Warmline, PEPline & OPA/OFP Conference March 17, 2012 Shannon Weber, MSW sweber@nccc.ucsf.edu Disclosure The following people have no relevant financial, professional or personal
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationSo you have HIV and you want to have a baby?
So you have HIV and you want to have a baby? Judy Levison, MD, MPH Associate Professor Department of Obstetrics and Gynecology Baylor College of Medicine Objectives Describe methods of safe conception
More informationFertility Management in HIV. INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute
Fertility Management in HIV INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute What to consider Does HIV affect fertility success?
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationThe Latest on HIV Testing. Dominika Seidman, MD MAS
The Latest on HIV Testing Dominika Seidman, MD MAS Disclosures none 2 Learning objectives At the conclusion of this session, participants should be able to Define the window periods for various HIV tests
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationPRECONCEPTION COUNSELING
PRECONCEPTION COUNSELING A Counseling Guide for Healthcare Providers Preconception Care & Counseling 1 Introduction Pregnancy planning and preconception care are important in order to: 1. Ensure maternal
More informationHIV Prevention and Reproductive Choices
HIV Prevention and Reproductive Choices Renee Heffron, PhD MPH University of Washington Virology Education International Workshop on HIV & Women Boston, 20-21 February 2016 Reproductive choices & pregnancy
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationContraception & HIV Still searching for answers after >2 decades
Contraception & HIV Still searching for answers after >2 decades R Scott McClelland, MD, MPH University of Washington Inter CFAR Symposium on HIV Research in Women September 20 th 2012 Overview Global
More informationGuidelines on safer conception in fertile HIV infected individuals
Guidelines on safer conception in fertile HIV infected individuals couples Vivian Black Co-authors: L-G Bekker, H Rees, S Black, D Cooper, S Mall, C Mnyami, F Conradie, I Mahabeer, L Gilbert, S Schwartz,
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationHIV PREP THE NEWEST TOOL IN THE BOX
HIV PREP THE NEWEST TOOL IN THE BOX Infectious Disease Update November 7, 2014 Andrew Petroll, MD, MS Department of Medicine, Division of Infectious Diseases Department of Psychiatry and Behavioral Medicine,
More informationWHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015
WHO s early release guidelines on PrEP: implications for emtct Dominika Seidman, MD October 13, 2015 Outline Evidence behind WHO early release guidelines on PrEP PrEP eligibility according to the WHO Rationale
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationPrevention of Perinatal HIV Transmission
Prevention of Perinatal HIV Transmission Emily Adhikari, MD Division of Maternal-Fetal Medicine Obstetrics and Gynecology University of Texas Southwestern Medical Center February 20, 2018 None Understand
More informationUse of Pre-exposure Prophylaxis (PrEP) in pregnancy for primary prevention of HIV infection in women
Use of Pre-exposure Prophylaxis (PrEP) in pregnancy for primary prevention of HIV infection in women Catherine Hankins MD PhD FRCPC CM Deputy Director, Science Amsterdam Institute for Global Health and
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationDr Yvonne Gilleece Brighton and Sussex University Hospitals NHS Trust
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Yvonne Gilleece Brighton and Sussex University Hospitals NHS Trust 6-8 April 2011, Bournemouth International Centre Pre exposure prophylaxis
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D. HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (
More informationHIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic
HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic Yes No What s Going on Out There? Condomless Sex among
More informationI have no financial conflicts of interest to disclose.
12/9/16 Reproductive Health for Women And Men (!) Living with HIV in the US Deborah Cohan, MD, MPH Professor UCSF Dept of Obstetrics and Gynecology HIVE National Perinatal HIV Hotline Let s be in touch!
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationPre-exposure Prophylaxis and Primary Care
Pre-exposure Prophylaxis and Primary Care National Latino HIV and Hepatitis C Conference June 7 th, 2016 Allison Finkenbinder, MSN, WHNP-BC Denver Prevention Training Center Who s in the audience? Disclosures
More informationHigh Impact HIV Prevention Services and Best Practices
High Impact HIV Prevention Services and Best Practices David W. Purcell, JD, PhD Deputy Director for Behavioral and Social Science Division of HIV/AIDS Prevention Centers for Disease Control and Prevention
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationSo you want to have a baby? Pre-conception counselling for the HIV affected couple. Dr Louise Gilbert 23 November 2011
So you want to have a baby? Pre-conception counselling for the HIV affected couple Dr Louise Gilbert 23 November 2011 Meet Miss LM A 30 yr old lady HIV positive, well, on ART for the past 5 years Latest
More informationContraception for Women and Couples with HIV. Knowledge Test
Contraception for Women and Couples with HIV Knowledge Test Instructions: For each question below, check/tick all responses that apply. 1. Which statements accurately describe the impact of HIV/AIDS in
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationPre-exposure Prophylaxis (PrEP)
Pre-exposure Prophylaxis (PrEP) Kenneth Mayer, MD Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School and School of Public Health Treatment As Prevention in Africa Workshop May 2
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationFertility Therapy for Women & their Partners Affected by HIV. J. Preston Parry, MD, MPH
Fertility Therapy for Women & their Partners Affected by HIV J. Preston Parry, MD, MPH Objectives To recognize historical barriers to care for women and their partners affected by HIV To understand evidence
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationThe Pregnancy Journey...
The Pregnancy Journey... when you are living with HIV Authors: Angelina Namiba, Jo Manchester and Lucy Osman If you, or your partner, is HIV positive and you want to get pregnant, or you are pregnant or
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationAntiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies
Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies Craig W. Hendrix, MD Director, Drug Development Unit Division of Clinical Pharmacology Johns Hopkins University
More informationLARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures
LARC: Long Acting Reversible Contraception Disclosures I have no relevant financial disclosures Jennifer Kerns, MD, MPH Assistant Professor, UCSF Obstetrics, Gynecology and Reproductive Sciences San Francisco
More informationDominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis
Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis Charpentier, Harm Reduction Services Branch, Hawaii
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationduring conception, pregnancy and lactation at 2 U.S. medical centers
Use of HIV preexposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers Dominika Seidman, MD Shannon Weber, Maria Teresa Timoney, Karishma Oza, Elizabeth Mullins, Rodney
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationThe Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.
The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings Counseling Cards Checklist to be reasonably sure a woman is not pregnant
More informationTHIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE
THIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE The following content is provided for informational purposes only. Continuing CE Education HIV PRE-EXPOSURE PROPHYLAXIS: A REVIEW Release Date:
More informationReproductive Health Care: Agenda. Reproductive Health Care: Reproductive Life Plans. Reproductive Life Plans: Provider Prospective
Agenda An Integrated Approach Kimberly McClellan, MSN, WHNP-BC, CRNP Family Planning Council April 11, 2013 Primary Care Reproductive Health HIV Services Context for Integrative Services Contraceptive
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationLong-Acting Reversible Contraception: The Contraceptive CHOICE Project
Long-Acting Reversible Contraception: The Contraceptive CHOICE Project Jeffrey F. Peipert, M.D., Ph.D. Vice Chair of Clinical Research Robert J. Terry Professor Department of Obstetrics & Gynecology Washington
More informationDREAMS TO REALITY. Family Building for Men and Women Living with HIV PATH2PARENTHOOD. path2parenthood.org/hiv
DREAMS TO REALITY Family Building for Men and Women Living with HIV PATH2PARENTHOOD path2parenthood.org/hiv ARE YOU HIV POSITIVE, YET DREAM OF HAVING A FAMILY? If you are reading this handbook, you may
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationPre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationHIV - Preventing New Infections: New Options, Readjusted Approaches
HIV - Preventing New Infections: New Options, Readjusted Approaches Ronald P. Hattis, MD, MPH Beyond AIDS Foundation Presented at Loma Linda University December 6, 2013 1 Thesis (Summary) As of 2013-14,
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationGlobal Contraception
Video Companion Guide Global Contraception Learning Objectives: By the end of the session, learners will be able to: Describe of all contraceptive methods. Develop a basic understanding of patient-centered
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationCROI 2016 Update NEAETC, March 21, Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School
CROI 2016 Update NEAETC, March 21, 2016 Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School CROI 2016 Update NEAETC, March 21, 2016 UNITED STATES EPIDEMIOLOGY Estimating the lifetime risk
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationChapter 7 Infertility, Contraception, and Abortion
Chapter 7 Infertility, Contraception, and Abortion Infertility Incidence Affects about 10% to 15% of reproductive-age population Subfertility: prolonged time to conceive Sterility: inability to conceive
More informationPre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationThe Synergy between HIV and other STIs
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission
More informationThe Beginning of the End of AIDS Diane V. Havlir, MD
The Beginning of the End of AIDS Diane V. Havlir, MD Professor of Medicine University of California, San Francisco AIDS: The Beginning Friedman-Kien, Color Atlas of AIDS AIDS: The Middle Number of people
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationSimplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok
Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able
More informationProfilaxis Antiretroviral para la Prevención de la Infección VIH
1 Profilaxis Antiretroviral para la Prevención de la Infección VIH TAR precoz HIV + en pareja discordante Profilaxis pre exposición (PrEP) Celia Miralles Unidad de VIH H.lXeral Cies (CHUVI) Vigo 2 1 2
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More information